背景:PD-1抑制剂通过激活自身免疫耐受往往可以发挥意想不到的抗肿瘤效果。然而,PD-1抑制剂引起的过度激活的自身免疫系统可导致免疫相关不良事件(irAEs)的产生。因此,在临床治疗中有必要关注使用PD-1抑制剂患者可能发生的irAEs。方法:本研究回顾性评估了2019.04.01至2021.04.30就诊于浙江省人民医院的288例应用PD-1抑制剂的实体瘤患者。我们就irAEs的发生率、发生时间、发生谱、疗效相关性等进行探究。同时,我们进一步探讨了PD-1抑制剂在肺癌亚组中的治疗疗效。结果:在本研究所涉及的288例患者中,irAEs的总发生率为35.07%,I~II级irAEs和III~V级irAEs的发生率分别为30.38%、4.69%。甲状腺功能减退是最常见的irAEs,其次是肝功能损伤,接下来是皮肤反应、疲乏和免疫相关性肺炎。irAEs的中位发生时间为3.15个月(平均4.09个月,95% CI [3.43, 4.74])。发生irAEs的患者与无irAEs患者相比有更长的OS、PFS (mOS:10.80个月vs 6.32个月,P = 0.01;mPFS:8.95个月vs 4.73个月,P < 0.01),irAEs发生较晚患者较早发生患者OS、PFS有显著的改善(mOS:13.51个月vs 8.24个月,P < 0.01;mPFS:11.29个月vs 6.74个月,P < 0.01),但高级别irAEs并不意味着患者可获得更好的预后。各种irAEs在各瘤种发生率的差异均无统计学意义。在小细胞肺癌、肺腺癌和肺鳞癌中,与后线治疗相比,PD-1抑制剂在一线治疗均表现出更好生存获益的趋势。在肺腺癌和肺鳞癌的一线治疗中,与PD-1抑制剂联合化疗相比,PD-1抑制剂加化疗联合抗肿瘤药物显示出更好的联合疗效。结论及意义:在使用PD-1抑制剂治疗前需要进行全面的基线测量,以警惕irAEs的发生。irAEs发生类型与肿瘤类型无关,irAEs是否发生以及发生时间早晚有助于预测PD-1抑制剂的疗效。然而,高级别irAEs的存在并不意味着更好的疗效,这可能与治疗中断有关。对已发生高级别irAEs的患者,应按指南进行规范化管理,及时足量使用糖皮质激素甚至免疫抑制剂。在肺癌患者中,PD-1抑制剂联合抗血管生成药物和化疗可能具有协同效应。我们建议PD-1抑制剂应尽可能应用于肺癌的一线治疗。
Background: PD-1 inhibitors can often have unexpected anti-tumor effects by activating autoim-mune tolerance. However, over-activated autoimmune by PD-1 inhibitors responses can lead to immune-related adverse events (irAEs). Therefore, it is necessary to focus on the potential irAEs in patients on PD-1 inhibitors in daily clinical practice. Methods: This study retrospectively studied the case data of 288 patients with solid tumors who applied PD-1 inhibitors attending Zhejiang Pro-vincial People’s Hospital from 2019.04.01 to 2021.04.30. We analyzed the multiple aspects data of irAEs, such as the incidence, time, spectrum and efficacy correlation of it. In parallel, we further ex-plored the efficacy of PD-1 inhibitors for the lung cancer subgroup. Result: For 288 patients in our study, the total incidence of irAEs was 35.07%, and the incidence rate of grade I~II and III~V irAEs were 30.38% and 4.69% respectively. Hypothyroidism is the most common irAEs, followed by liver function injury, followed by skin reaction, weakness and immune-related pneumonia. The median onset time of irAEs was 3.15 months (mean time was 4.09 M, 95% CI [3.43, 4.74]). Compared with patients without irAEs, patients with irAEs had longer OS and PFS (mOS: 10.80 vs 6.32 months, P = 0.01; mPFS: 8.95 vs 4.73 months, P < 0.01). Patients with earlier irAEs had significantly improved OS and PFS (mOS: 13.51 vs 8.24 months, P < 0.01; mPFS: 11.29 vs 6.74 months, P < 0.01) than later irAEs, but high-level irAEs didn’t mean a better prognosis. There was no significant difference in the incidence of irAEs among tumor species. In SCLC, lung adenocarcinoma and lung squamous cell car-cinoma, PD-1 inhibitors showed a trend of better survival benefit in first-line treatment compared with later-line. In the first-line treatment of lung adenocarcinoma and lung squamous cell carcino-ma, compared with PD-1 inhibitor combined with chemotherapy, PD-1 inhibitors combined with chemotherapy and antiangiogenics show a better combined effect. Conclusion: Complete baseline measurements are required before treatment with PD-1 inhibitors to prevent the occurrence of irAEs. The irAEs was not related to the type of tumor. The presence and onset time of irAEs tends to predict the efficacy of PD-1 inhibitors. However, the presence of high-grade irAEs doesn’t indicate better outcomes. This may be related to treatment interruption. For patients with high-level irAEs, they should be standardized treat according to the guidelines and hormones and even immuno-suppressants should be used in sufficient quantities in time. In lung cancer patients, PD-1 inhibitors combined with antiangiogenics and chemotherapy may have a synergistic effect. We suggest that PD-1 inhibitors could be applied in first-line treatment of lung cancer if possible.
Background: PD-1 inhibitors can often have unexpected anti-tumor effects by activating autoimmune tolerance. However, over-activated autoimmune by PD-1 inhibitors responses can lead to immune-related adverse events (irAEs). Therefore, it is necessary to focus on the potential irAEs in patients on PD-1 inhibitors in daily clinical practice. Methods: This study retrospectively studied the case data of 288 patients with solid tumors who applied PD-1 inhibitors attending Zhejiang Provincial People’s Hospital from 2019.04.01 to 2021.04.30. We analyzed the multiple aspects data of irAEs, such as the incidence, time, spectrum and efficacy correlation of it. In parallel, we further explored the efficacy of PD-1 inhibitors for the lung cancer subgroup. Result: For 288 patients in our study, the total incidence of irAEs was 35.07%, and the incidence rate of grade I~II and III~V irAEs were 30.38% and 4.69% respectively. Hypothyroidism is the most common irAEs, followed by liver function injury, followed by skin reaction, weakness and immune-related pneumonia. The median onset time of irAEs was 3.15 months (mean time was 4.09 M, 95% CI [3.43, 4.74]). Compared with patients without irAEs, patients with irAEs had longer OS and PFS (mOS: 10.80 vs 6.32 months, P = 0.01; mPFS: 8.95 vs 4.73 months, P < 0.01). Patients with earlier irAEs had significantly improved OS and PFS (mOS: 13.51 vs 8.24 months, P < 0.01; mPFS: 11.29 vs 6.74 months, P < 0.01) than later irAEs, but high-level irAEs didn’t mean a better prognosis. There was no significant difference in the incidence of irAEs among tumor species. In SCLC, lung adenocarcinoma and lung squamous cell carcinoma, PD-1 inhibitors showed a trend of better survival benefit in first-line treatment compared with later-line. In the first-line treatment of lung adenocarcinoma and lung squamous cell carcinoma, compared with PD-1 inhibitor combined with chemotherapy, PD-1 inhibitors combined with chemotherapy and antiangiogenics show a better combined effect. Conclusion: Complete baseline measurements are required before treatment with PD-1 inhibitors to prevent the occurrence of irAEs. The irAEs was not related to the type of tumor. The presence and onset time of irAEs tends to predict the efficacy of PD-1 inhibitors. However, the presence of high-grade irAEs doesn’t indicate better outcomes. This may be related to treatment interruption. For patients with high-level irAEs, they should be standardized treat according to the guidelines and hormones and even immunosuppressants should be used in sufficient quantities in time. In lung cancer patients, PD-1 inhibitors combined with antiangiogenics and chemotherapy may have a synergistic effect. We suggest that PD-1 inhibitors could be applied in first-line treatment of lung cancer if possible.
陈运旺,姜丁乙,邓亚亚,张馨月,陈哲灵,杨 柳. PD-1抑制剂所致免疫相关不良事件的真实世界研究Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors[J]. 临床医学进展, 2022, 12(06): 5913-5936. https://doi.org/10.12677/ACM.2022.126856
参考文献ReferencesO’Neill, R.E. and Cao, X. (2019) Co-Stimulatory and Co-Inhibitory Pathways in Cancer Immunotherapy. Advances in Cancer Research, 143, 145-194. <br>https://doi.org/10.1016/bs.acr.2019.03.003Salmaninejad, A., Valilou, S.F., Shabgah, A.G., et al. (2019) PD-1/PD-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy. Journal of Cel-lular Physiology, 234, 16824-16837. <br>https://doi.org/10.1002/jcp.28358Baumeister, S.H., Freeman, G.J., Dranoff, G., et al. (2016) Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 34, 539-573. <br>https://doi.org/10.1146/annurev-immunol-032414-112049Hosseini, A., Gharibi, T., Marofi, F., et al. (2020) CTLA-4: From Mechanism to Autoimmune Therapy. International Immunopharmacology, 80, Article ID: 106221. <br>https://doi.org/10.1016/j.intimp.2020.106221Wei, S.C., Duffy, C.R. and Allison, J.P. (2018) Fun-damental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. <br>https://doi.org/10.1158/2159-8290.CD-18-0367Hargadon, K.M., Johnson, C.E. and Williams, C.J. (2018) Immune Checkpoint Blockade Therapy for Cancer: An Overview of FDA-Approved Immune Checkpoint Inhibitors. In-ternational Immunopharmacology, 62, 29-39.
<br>https://doi.org/10.1016/j.intimp.2018.06.001Chen, R., Ganesan, A., Okoye, I., et al. (2020) Targeting B7-1 in Immunotherapy. Medicinal Research Reviews, 40, 654-682. <br>https://doi.org/10.1002/med.21632Pentcheva-Hoang, T., Egen, J.G., Wojnoonski, K., et al. (2004) B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse. Immunity, 21, 401-413. <br>https://doi.org/10.1016/j.immuni.2004.06.017Rowshanravan, B., Halliday, N. and Sansom, D.M. (2018) CTLA-4: A Moving Target in Immunotherapy. Blood, 131, 58-67. <br>https://doi.org/10.1182/blood-2017-06-741033Hui, E., Cheung, J., Zhu, J., et al. (2017) T Cell Costimulatory Receptor CD28 Is a Primary Target for PD-1-Mediated Inhibition. Science, 355, 1428-1433. <br>https://doi.org/10.1101/086652Kamphorst, A.O., Wieland, A., Nasti, T., et al. (2017) Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies Is CD28-Dependent. Science, 355, 1423-1427. <br>https://doi.org/10.1126/science.aaf0683Bhatia, A. and Kumar, Y. (2014) Cellular and Molecular Mechanisms in Cancer Immune Escape: A Comprehensive Review. Expert Review of Clinical Immunology, 10, 41-62. <br>https://doi.org/10.1586/1744666X.2014.865519Demaria, O., Cornen, S., Daeron, M., et al. (2019) Harness-ing Innate Immunity in Cancer Therapy. Nature, 574, 45-56.
<br>https://doi.org/10.1038/s41586-019-1593-5Yang, Y. (2015) Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer. Journal of Clinical Investigation, 125, 3335-3337. <br>https://doi.org/10.1172/JCI83871Winograd, R., Byrne, K.T., Evans, R.A., et al. (2015) Induction of T-Cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carci-noma. Cancer Immunology Research, 3, 399-411. <br>https://doi.org/10.1158/2326-6066.CIR-14-0215Kennedy, L.B. and Salama, A.K.S. (2020) A Review of Cancer Immunotherapy Toxicity. CA: A Cancer Journal for Clinicians, 70, 86-104. <br>https://doi.org/10.3322/caac.21596Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, 38. <br>https://doi.org/10.1038/s41572-020-0160-6Liu, Y.H., Zang, X.Y., Wang, J.C., et al. (2019) Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomedicine & Pharmacotherapy, 120, Article ID: 109437.
<br>https://doi.org/10.1016/j.biopha.2019.109437Weber, J.S., Postow, M., Lao, C.D., et al. (2016) Management of Adverse Events Following Treatment with Anti-Programmed Death-1 Agents. Oncologist, 21, 1230-1240. <br>https://doi.org/10.1634/theoncologist.2016-0055Darnell, E.P., Mooradian, M.J., Baruch, E.N., et al. (2020) Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 22, 39. <br>https://doi.org/10.1007/s11912-020-0897-9Friedman, C.F., Proverbs-Singh, T.A. and Postow, M.A. (2016) Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncology, 2, 1346-1353.
<br>https://doi.org/10.1001/jamaoncol.2016.1051Das, S. and Johnson, D.B. (2019) Immune-Related Adverse Events and Anti-Tumor Efficacy of Immune Checkpoint Inhibitors. Journal for ImmunoTherapy of Cancer, 7, 306. <br>https://doi.org/10.1186/s40425-019-0805-8Sugano, T., Seike, M., Saito, Y., et al. (2020) Immune Check-point Inhibitor-Associated Interstitial Lung Diseases Correlate with Better Prognosis in Patients with Advanced Non-Small-Cell Lung Cancer. Thoracic Cancer, 11, 1052-1060. <br>https://doi.org/10.1111/1759-7714.13364Shankar, B., Zhang, J., Naqash, A.R., et al. (2020) Multisystem Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncology, 6, 1952-1956.
<br>https://doi.org/10.1001/jamaoncol.2020.5012Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
<br>https://doi.org/10.1016/j.ejca.2008.10.026Wang, P.F., Chen, Y., Song, S.Y., et al. (2017) Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Frontiers in Phar-macology, 8, Article No. 730.
<br>https://doi.org/10.3389/fphar.2017.00730Xu, C., Chen, Y.P., Du, X.J., et al. (2018) Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis. British Medical Journal, 363, k4226. <br>https://doi.org/10.1136/bmj.k4226Ja, L.G. and Sher, A. (2020) Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. Cancer Investigation, 38, 365-371.
<br>https://doi.org/10.1080/07357907.2020.1783677Khoja, L., Day, D., Chen, T.W.W., et al. (2017) Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28, 2377-2385. <br>https://doi.org/10.1093/annonc/mdx286Rogado, J., Sanchez-Torres, J.M., Romero-Laorden, N., et al. (2019) Immune-Related Adverse Events Predict the Therapeutic Efficacy of Anti-PD-1 Antibodies in Cancer Patients. European Journal of Cancer, 109, 21-27.
<br>https://doi.org/10.1016/j.ejca.2018.10.014Akamatsu, H., Murakami, E., Oyanagi, J., et al. (2020) Im-mune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Re-sponders with Advanced Non-Small Cell Lung Cancer. Oncologist, 25, e679-e683. <br>https://doi.org/10.1634/theoncologist.2019-0299Robert, C., Hwu, W.J., Hamid, O., et al. (2021) Long-Term Safety of Pembrolizumab Monotherapy and Relationship with Clinical Outcome: A Landmark Analysis in Patients with Advanced Melanoma. European Journal of Cancer, 144, 182-191. <br>https://doi.org/10.1016/j.ejca.2020.11.010Robert, C., Ribas, A., Wolchok, J.D., et al. (2014) An-ti-Programmed-Death-Receptor-1 Treatment with Pembrolizumab in Ipilimumab-Refractory Advanced Melanoma: A Randomised Dose-Comparison Cohort of a Phase 1 Trial. The Lancet, 384, 1109-1117. <br>https://doi.org/10.1016/S0140-6736(14)60958-2Ribas, A., Puzanov, I., Dummer, R., et al. (2015) Pem-brolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): A Ran-domised, Controlled, Phase 2 Trial. The Lancet Oncology, 16, 908-918. <br>https://doi.org/10.1016/S1470-2045(15)00083-2Schachter, J., Ribas, A., Long, G.V., et al. (2017) Pem-brolizumab versus Ipilimumab for Advanced Melanoma: Final Overall Survival Results of a Multicentre, Randomised, Open-Label Phase 3 Study (KEYNOTE-006). The Lancet, 390, 1853-1862. <br>https://doi.org/10.1016/S0140-6736(17)31601-XNg, K.Y.Y., Tan, S.H., Tan, J.J.E., et al. (2022) Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 11, 9-21.
<br>https://doi.org/10.1159/000518619Hussaini, S., Chehade, R., Boldt, R.G., et al. (2021) Association between Immune-Related Side Effects and Efficacy and Benefit of Immune Checkpoint Inhibitors—A Systematic Review and Meta-Analysis. Cancer Treatment Reviews, 92, Article ID: 102134. <br>https://doi.org/10.1016/j.ctrv.2020.102134Khan, S. and Gerber, D.E. (2020) Autoimmunity, Checkpoint In-hibitor Therapy and Immune-Related Adverse Events: A Review. Seminars in Cancer Biology, 64, 93-101. <br>https://doi.org/10.1016/j.semcancer.2019.06.012Haanen, J., Carbonnel, F., Robert, C., et al. (2017) Man-agement of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 28, iv119-iv142.
<br>https://doi.org/10.1093/annonc/mdx225Teufel, A., Zhan, T., Hartel, N., et al. (2019) Management of Immune Related Adverse Events Induced by Immune Checkpoint Inhibition. Cancer Letters, 456, 80-87. <br>https://doi.org/10.1016/j.canlet.2019.04.018Reck, M., Mok, T.S.K., Nishio, M., et al. (2019) Atezolizumab Plus Bevacizumab and Chemotherapy in Non-Small- Cell Lung Cancer (IMpower150): Key Subgroup Analyses of Pa-tients with EGFR Mutations or Baseline Liver Metastases in a Randomised, Open-Label Phase 3 Trial. The Lancet Res-piratory Medicine, 7, 387-401.
<br>https://doi.org/10.1016/S2213-2600(19)30084-0West, H., Mccleod, M., Hussein, M., et al. (2019) Atezoli-zumab in Combination with Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Ran-domised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 924-937.
<br>https://doi.org/10.1016/S1470-2045(19)30167-6Nishio, M., Barlesi, F., West, H., et al. (2021) Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results from the Randomized Phase 3 IMpow-er132 Trial. Journal of Thoracic Oncology, 16, 653-664. <br>https://doi.org/10.1016/j.jtho.2020.11.025Lee, P.Y., Oen, K.Q.X., Lim, G.R.S., et al. (2021) Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Ad-verse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. Cancers, 13, Article No. 1308. <br>https://doi.org/10.3390/cancers13061308Peng, L., Wang, Y., Liu, F., et al. (2020) Peripheral Blood Markers Predictive of Outcome and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors. Cancer Immunology, Immunotherapy, 69, 1813-1822. <br>https://doi.org/10.1007/s00262-020-02585-wKos, F.T., Hocazade, C., Kos, M., et al. (2015) Assessment of Prognostic Value of “Neutrophil to Lymphocyte Ratio” and “Prognostic Nutritional Index” as a Sytemic Inflammatory Marker in Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 16, 3997-4002. <br>https://doi.org/10.7314/APJCP.2015.16.9.3997Miyazaki, T., Sakai, M., Sohda, M., et al. (2016) Prognostic Significance of Inflammatory and Nutritional Parameters in Patients with Esophageal Cancer. Anticancer Research, 36, 6557-6562. <br>https://doi.org/10.21873/anticanres.11259Thompson, J.A., Schneider, B.J., Brahmer, J., et al. (2020) NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18, 230-241.
<br>https://doi.org/10.6004/jnccn.2020.0012Haanen, J., Carbonnel, F., Robert, C., et al. (2018) Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29, iv264-iv266. <br>https://doi.org/10.1093/annonc/mdy162Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statis-tics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Can-cer Journal for Clinicians, 71, 209-249.
<br>https://doi.org/10.3322/caac.21660Kalemkerian, G.P., Loo, B.W., Akerley, W., et al. (2018) NCCN Guide-lines Insights: Small Cell Lung Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network, 16, 1171-1182.
<br>https://doi.org/10.6004/jnccn.2018.0079Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 19, 254-266.Antonia, S.J., López-Martin, J.A., Bendell, J., et al. (2016) Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, 883-895. <br>https://doi.org/10.1016/S1470-2045(16)30098-5Spigel, D.R., Vicente, D., Ciuleanu, T.E., et al. (2021) Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. Annals of Oncology, 32, 631-641. <br>https://doi.org/10.1016/j.annonc.2021.01.071Owonikoko, T.K., Park, K., Govindan, R., et al. (2021) Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39, 1349-1359.Chung, H.C., Piha-Paul, S.A., Lopez-Martin, J., et al. (2020) Pembrolizumab after Two or More Lines of Previous Therapy in Patients with Recurrent or Metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 15, 618-627. <br>https://doi.org/10.1016/j.jtho.2019.12.109Rudin, C.M., Awad, M.M., Navarro, A., et al. (2020) Pembroli-zumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Ran-domized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 2369-2379.Zhou, Y., Chen, C., Zhang, X., et al. (2018) Immune-Checkpoint In-hibitor Plus Chemotherapy versus Conventional Chemotherapy for First-Line Treatment in Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Journal for ImmunoTherapy of Cancer, 6, 155. <br>https://doi.org/10.1186/s40425-018-0477-9O’Donnell, J.S., Hoefsmit, E.P., Smyth, M.J., et al. (2019) The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clinical Cancer Research, 25, 5743-5751. <br>https://doi.org/10.1158/1078-0432.CCR-18-2641Topalian, S.L., Taube, J.M. and Pardoll, D.M. (2020) Ne-oadjuvant Checkpoint Blockade for Cancer Immunotherapy. Science, 367, eaax0182. <br>https://doi.org/10.1126/science.aax0182Landre, T., Des Guetz, G., Chouahnia, K., et al. (2020) Immune Checkpoint Inhibitors for Patients Aged ≥75 Years with Advanced Cancer in First- and Second-Line Settings: A Me-ta-Analysis. Drugs & Aging, 37, 747-754.
<br>https://doi.org/10.1007/s40266-020-00788-5Liu, J., Blake, S.J., Yong, M.C., et al. (2016) Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discovery, 6, 1382-1399. <br>https://doi.org/10.1158/2159-8290.CD-16-0577Provencio, M., Nadal, E., Insa, A., et al. (2020) Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1413-1422. <br>https://doi.org/10.1016/S1470-2045(20)30453-8Kalemkerian, G.P., Narula, N., Kennedy, E.B., et al. (2018) Molecular Testing Guideline for the Selection of Patients with Lung Cancer for Treatment with Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36, 911-919.Park, K., Vansteenkiste, J., Lee, K.H., et al. (2020) Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Locally-Advanced Unresectable Non-Small-Cell Lung Cancer: A KSMO-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Annals of Oncology, 31, 191-201.
<br>https://doi.org/10.1016/j.annonc.2019.10.026Garcia, J., Hurwitz, H.I., Sandler, A.B., et al. (2020) Bevaci-zumab (Avastin®) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook. Cancer Treatment Reviews, 86, Article ID: 102017.
<br>https://doi.org/10.1016/j.ctrv.2020.102017Assoun, S., Brosseau, S., Steinmetz, C., et al. (2017) Bevaci-zumab in Advanced Lung Cancer: State of the Art. Future Oncology, 13, 2515-2535. <br>https://doi.org/10.2217/fon-2017-0302Abdollahi, A., Hlatky, L. and Huber, P.E. (2005) Endostatin: The Logic of Antiangiogenic Therapy. Drug Resistance Updates, 8, 59-74. <br>https://doi.org/10.1016/j.drup.2005.03.001Folkman, J. (2006) Antiangiogenesis in Cancer Thera-py—Endostatin and Its Mechanisms of Action. Experimental Cell Research, 312, 594-607. <br>https://doi.org/10.1016/j.yexcr.2005.11.015Poluzzi, C., Iozzo, R.V. and Schaefer, L. (2016) Endostatin and Endorepellin: A Common Route of Action for Similar Angiostatic Cancer Avengers. Advanced Drug Delivery Reviews, 97, 156-173.
<br>https://doi.org/10.1016/j.addr.2015.10.012Montanino, A., Manzo, A., Carillio, G., et al. (2021) Angiogene-sis Inhibitors in Small Cell Lung Cancer. Frontiers in Oncology, 11, Article ID: 655316.Sun, Y., Wang, J.W., Liu, Y.Y., et al. (2013) Long-Term Results of a Randomized, Double-Blind, and Placebo-Controlled Phase III Trial: Endostar (rh-Endostatin) versus Placebo in Combination with Vinorelbine and Cisplatin in Advanced Non-Small Cell Lung Cancer. Thoracic Cancer, 4, 440-448. <br>https://doi.org/10.1111/1759-7714.12050Li, Y., Yi, Y., Lin, A., et al. (2020) A Comparison of the Efficacy of Antiangiogenic Agents Combined with Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis. Cancer Cell International, 20, 548. <br>https://doi.org/10.1186/s12935-020-01639-4Wang, P.L., Fang, X.Z., Yin, T.W., et al. (2021) Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients with Advanced Non-Small-Cell Lung Cancer after Previous Systemic Treatment Failure—A Retrospective Study. Frontiers in Oncology, 11, Article ID: 628124. <br>https://doi.org/10.3389/fonc.2021.628124Proto, C., Ferrara, R., Signorelli, D., et al. (2019) Choosing Wisely First Line Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): What to Add and What to Leave out. Cancer Treatment Reviews, 75, 39-51.
<br>https://doi.org/10.1016/j.ctrv.2019.03.004Arneth, B. (2019) Tumor Microenvironment. Medicina, 56, Article No. 15. <br>https://doi.org/10.3390/medicina56010015Vitale, I., Manic, G., Coussens, L.M., et al. (2019) Mac-rophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 30, 36-50. <br>https://doi.org/10.1016/j.cmet.2019.06.001Denton, A.E., Roberts, E.W. and Fearon. D.T. (2018) Stromal Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 1060, 99-114. <br>https://doi.org/10.1007/978-3-319-78127-3_6Labani-Motlagh, A., Ashja-Mahdavi, M. and Loskog, A. (2020) The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Frontiers in Immunology, 11, Article No. 940.
<br>https://doi.org/10.3389/fimmu.2020.00940Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Can-cer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. <br>https://doi.org/10.1016/j.immuni.2019.06.025Lim, A.R., Rathmell, W.K. and Rathmell, J.C. (2020) The Tu-mor Microenvironment as a Metabolic Barrier to Effector T Cells and Immunotherapy. eLife, 9, e55185. <br>https://doi.org/10.7554/eLife.55185Binnewies, M., Roberts, E.W., Kersten, K., et al. (2018) Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nature Medicine, 24, 541-550. <br>https://doi.org/10.1038/s41591-018-0014-xShi, R., Liao, C.H. and Zhang, Q. (2021) Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications. Cells, 10, Article No. 678. <br>https://doi.org/10.3390/cells10030678Boedtkjer, E. and Pedersen, S.F. (2020) The Acidic Tumor Microen-vironment as a Driver of Cancer. Annual Review of Physiology, 82, 103-126. <br>https://doi.org/10.1146/annurev-physiol-021119-034627Estrella, V., Chen, T., Lloyd, M., et al. (2013) Acid-ity Generated by the Tumor Microenvironment Drives Local Invasion. Cancer Research, 73, 1524-1535. <br>https://doi.org/10.1158/0008-5472.CAN-12-2796Nakamura, K. and Smyth, M.J. (2017) Targeting Can-cer-Related Inflammation in the Era of Immunotherapy. Immunology & Cell Biology, 95, 325-332. <br>https://doi.org/10.1038/icb.2016.126Shimizu, K., Iyoda, T., Okada, M., et al. (2018) Immune Suppression and Reversal of the Suppressive Tumor Microenvironment. International Immunology, 30, 445-454. <br>https://doi.org/10.1093/intimm/dxy042Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in Cancer and Other Diseases. Nature: International Weekly Journal of Science, 407, 249-257. <br>https://doi.org/10.1038/35025220Schito, L. and Semenza, G.L. (2016) Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. Trends in Cancer, 2, 758-770. <br>https://doi.org/10.1016/j.trecan.2016.10.016Fukumura, D., Kloepper, J., Amoozgar, Z., et al. (2018) En-hancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges. Nature Reviews Clinical Oncolo-gy, 15, 325-340.
<br>https://doi.org/10.1038/nrclinonc.2018.29Schmittnaegel, M., Rigamonti, N., Kadioglu, E., et al. (2017) Dual Angiopoietin-2 and VEGFA Inhibition Elicits Antitumor Immunity that Is Enhanced by PD-1 Checkpoint Blockade. Science Translational Medicine, 9.
<br>https://doi.org/10.1126/scitranslmed.aak9670Yasuda, S., Sho, M., Yamato, I., et al. (2013) Simultaneous Blockade of Programmed Death 1 and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Induces Synergistic Anti-Tumour Effect in Vivo. Clinical & Experimental Immunology, 172, 500-506. <br>https://doi.org/10.1111/cei.12069Wu, F.T.H., Xu, P., Chow, A., et al. (2019) Pre- and Post-Operative an-ti-PD-L1 Plus Anti-Angiogenic Therapies in Mouse Breast Or Renal Cancer Models of Micro- or Macro-Metastatic Disease. British Journal of Cancer, 120, 196-206. <br>https://doi.org/10.1038/s41416-018-0297-1Wang, Q., Gao, J., Di, W., et al. (2020) Anti-Angiogenesis Therapy Overcomes the Innate Resistance to PD-1/PD-L1 Blockade in VEGFA-Overexpressed Mouse Tumor Models. Cancer Immunology, Immunotherapy, 69, 1781-1799.
<br>https://doi.org/10.1007/s00262-020-02576-xJain, R.K. (2014) Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 26, 605-622. <br>https://doi.org/10.1016/j.ccell.2014.10.006Yi, M., Jiao, D., Qin, S., et al. (2019) Synergistic Effect of Im-mune Checkpoint Blockade and Anti-Angiogenesis in Cancer Treatment. Molecular Cancer, 18, Article No. 60. <br>https://doi.org/10.1186/s12943-019-0974-6Mcdermott, D.F., Huseni, M.A., Atkins, M.B., et al. (2018) Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab versus Sunitinib in Renal Cell Carcinoma. Nature Medicine, 24, 749-757. <br>https://doi.org/10.1038/s41591-018-0053-3Rini, B.I., Powles, T., Atkins, M.B., et al. (2019) Atezolizumab Plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmo-tion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial. The Lancet, 393, 2404-2415. <br>https://doi.org/10.1016/S0140-6736(19)30723-8Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. <br>https://doi.org/10.1056/NEJMoa1915745Lee, M.S., Ryoo, B.Y., Hsu, C.H., et al. (2020) Atezolizumab with or without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-Label, Multicentre, Phase 1b Study. The Lancet Oncology, 21, 808-820.
<br>https://doi.org/10.1016/S1470-2045(20)30156-X